A Randomized Trial of 13-Cis Retinoic Acid in Children With Advanced Neuroblastoma After High-Dose Therapy

Br J Cancer. 2000 Nov;83(9):1124-7. doi: 10.1054/bjoc.2000.1425.

Abstract

One hundred and seventy-five children with Stage 3 or 4 neuroblastoma who had obtained a good response to conventional therapy were randomly allocated to 13-Cis retinoic acid at a dose of 0.75 mg/kg/day or placebo for up to 4 years. Toxicity was mild but no advantage in event-free survival was shown for the children receiving retinoic acid.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Cheilitis / chemically induced
  • Child
  • Child, Preschool
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Follow-Up Studies
  • Humans
  • Infant
  • Isotretinoin / adverse effects
  • Isotretinoin / therapeutic use*
  • Melphalan / therapeutic use
  • Neoplasm Staging
  • Neoplasm, Residual / drug therapy
  • Neoplasm, Residual / pathology
  • Neuroblastoma / drug therapy*
  • Neuroblastoma / mortality
  • Neuroblastoma / pathology
  • Skin Diseases / chemically induced
  • Survival Analysis
  • Survival Rate
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Alkylating
  • Isotretinoin
  • Melphalan